Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Markovic

Showing results (281-290 of 368) with videos related to

Pageof 37
Sort By:
Haematologica|October 14, 2011
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphomaLuis F Porrata, Kay Ristow, Joseph P Colgan, et al.
British Journal of Haematology|February 25, 2012
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphomaLuis F Porrata, Kay Ristow, Thomas M Habermann, et al.
British Journal of Haematology|April 4, 2008
Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemiaShanique Palmer, Curtis A Hanson, Clive S Zent, et al.
British Journal of Haematology|April 17, 2007
Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomasDeepti Behl, Kay Ristow, Svetomir N Markovic, et al.
Journal of the National Cancer Institute|September 20, 2017
Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant TherapyStefan Suciu, Alexander M M Eggermont, Paul Lorigan, et al.
Blood|July 27, 2001
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphomaL F Porrata, M A Gertz, D J Inwards, et al.
Leukemia|May 21, 2010
Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphomaL F Porrata, K Rsitow, D J Inwards, et al.
Oncotarget|March 16, 2018
Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF <sup></sup> -mutant melanomaAntoneicka L Harris, Samantha E Lee, Louis K Dawson, et al.
American Journal of Clinical Oncology|August 8, 2006
Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunizationSvetomir N Markovic, Vera J Suman, James N Ingle, et al.
Eye (London, England)|June 22, 2013
Dermal and conjunctival melanocytic proliferations in diffuse uveal melanocytic proliferationJ S Pulido, T J Flotte, H Raja, et al.
Pageof 37

Showing results (281-290 of 368) with videos related to

Sort By:
Pageof 37
Haematologica|October 14, 2011
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphomaLuis F Porrata, Kay Ristow, Joseph P Colgan, et al.
British Journal of Haematology|February 25, 2012
Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphomaLuis F Porrata, Kay Ristow, Thomas M Habermann, et al.
British Journal of Haematology|April 4, 2008
Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemiaShanique Palmer, Curtis A Hanson, Clive S Zent, et al.
British Journal of Haematology|April 17, 2007
Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomasDeepti Behl, Kay Ristow, Svetomir N Markovic, et al.
Journal of the National Cancer Institute|September 20, 2017
Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant TherapyStefan Suciu, Alexander M M Eggermont, Paul Lorigan, et al.
Blood|July 27, 2001
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphomaL F Porrata, M A Gertz, D J Inwards, et al.
Leukemia|May 21, 2010
Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphomaL F Porrata, K Rsitow, D J Inwards, et al.
Oncotarget|March 16, 2018
Targeting the cyclin dependent kinase and retinoblastoma axis overcomes standard of care resistance in BRAF <sup></sup> -mutant melanomaAntoneicka L Harris, Samantha E Lee, Louis K Dawson, et al.
American Journal of Clinical Oncology|August 8, 2006
Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunizationSvetomir N Markovic, Vera J Suman, James N Ingle, et al.
Eye (London, England)|June 22, 2013
Dermal and conjunctival melanocytic proliferations in diffuse uveal melanocytic proliferationJ S Pulido, T J Flotte, H Raja, et al.
Pageof 37